NASDAQ:TMDXTransMedics Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TransMedics Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.08 -0.13 (-0.98 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$12.75Now: $13.08▼$13.6450-Day Range$13.21MA: $15.98▼$18.2652-Week Range$10.10Now: $13.08▼$30.17Volume285,705 shsAverage Volume157,574 shsMarket Capitalization$279.41 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, TransMedics Group has a potential upside of 68.2% from its current price of $13.08.Amount of Analyst CoverageTransMedics Group has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesTransMedics Group has received 44 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTransMedics Group has received 48 “underperform” votes. (Add your “underperform” vote.)Community SentimentTransMedics Group has received 52.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote “Outperform” if you believe TMDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $240,300.00 in company stock.Percentage Held by InsidersOnly 13.10% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions70.59% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($1.70) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMDX Previous Symbol CUSIPN/A CIKN/A Webwww.transmedics.com Phone978-552-0900Debt Debt-to-Equity Ratio0.73 Current Ratio6.10 Quick Ratio5.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.60 million Price / Sales11.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book5.07Profitability EPS (Most Recent Fiscal Year)($2.36) Net Income$-33,550,000.00 Net Margins-134.19% Return on Equity-60.19% Return on Assets-32.58%Miscellaneous EmployeesN/A Outstanding Shares21,362,000Market Cap$279.41 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:TMDX Rates by TradingView Receive TMDX News and Ratings via Email Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)? TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has decreased by 4.0% and is now trading at $13.08. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TransMedics Group? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group. When is TransMedics Group's next earnings date? TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransMedics Group. How were TransMedics Group's earnings last quarter? TransMedics Group Inc (NASDAQ:TMDX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.02. The company had revenue of $7.53 million for the quarter, compared to analysts' expectations of $7.49 million. TransMedics Group had a negative return on equity of 60.19% and a negative net margin of 134.19%. View TransMedics Group's earnings history. What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.4-7.5 million, compared to the consensus revenue estimate of $6.87 million. What price target have analysts set for TMDX? 4 analysts have issued 1-year price targets for TransMedics Group's shares. Their forecasts range from $16.00 to $28.00. On average, they anticipate TransMedics Group's stock price to reach $22.00 in the next year. This suggests a possible upside of 68.2% from the stock's current price. View analysts' price targets for TransMedics Group. Has TransMedics Group been receiving favorable news coverage? News stories about TMDX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. TransMedics Group earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTransMedics Group. Are investors shorting TransMedics Group? TransMedics Group saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,310,000 shares, a decrease of 5.8% from the April 15th total of 1,390,000 shares. Based on an average daily volume of 136,000 shares, the days-to-cover ratio is currently 9.6 days. Approximately 8.3% of the company's stock are short sold. View TransMedics Group's Current Options Chain. Who are some of TransMedics Group's key competitors? Some companies that are related to TransMedics Group include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), AxoGen (AXGN), BioLife Solutions (BLFS), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), BioSig Technologies (BSGM), Cutera (CUTR), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), Fc Global Realty (FCRE) and electroCore (ECOR). View all competitors. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AT&T (T), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Beyond Meat (BYND), Walt Disney (DIS) and Etsy (ETSY). Who are TransMedics Group's key executives? TransMedics Group's management team includes the following people: Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)Mr. John F. Carey, VP of Operations (Age 55)Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)Mr. Brian Thomson, VP of HR (Age 51) When did TransMedics Group IPO? (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. What is TransMedics Group's stock symbol? TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX." Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.06%), Federated Hermes Inc. (2.28%), Zimmer Partners LP (2.20%), Emerald Advisers LLC (2.12%), Emerald Mutual Fund Advisers Trust (1.99%) and Massachusetts Financial Services Co. MA (1.21%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr, John F Carey, Stephen Gordon and Tamer I Khayal. View institutional ownership trends for TransMedics Group. Which institutional investors are selling TransMedics Group stock? TMDX stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Morgan Stanley, Roubaix Capital LLC, Zimmer Partners LP, UBS Group AG, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold TransMedics Group company stock in the last year include John F Carey, Stephen Gordon, and Tamer I Khayal. View insider buying and selling activity for TransMedics Group. Which institutional investors are buying TransMedics Group stock? TMDX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Taylor Wealth Management Partners, State Street Corp, Bullseye Asset Management LLC, Geode Capital Management LLC, AXA, and Bank of New York Mellon Corp. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr. View insider buying and selling activity for TransMedics Group. How do I buy shares of TransMedics Group? Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TransMedics Group's stock price today? One share of TMDX stock can currently be purchased for approximately $13.08. How big of a company is TransMedics Group? TransMedics Group has a market capitalization of $279.41 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. What is TransMedics Group's official website? The official website for TransMedics Group is www.transmedics.com. How can I contact TransMedics Group? TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
